USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
BCN BIOSCIENCES, LLC
Address:
BCN BIOSCIENCES, LLC
2275 E FOOTHILL BLVD
PASADENA, CA 91107 3658
Phone:
N/A
URL:
N/A
EIN:
133114620
DUNS:
788136880
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $390,452.00 3

Award List:

Translational research in a novel anti cancer agent

Award Year / Program / Phase:
2008 / SBIR / Phase I
Award Amount:
$99,510.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Natural products possess the richest source of molecular diversity in existence. In the case of cancer therapeutics, natural products have yielded a significant number of novel and effective cancer treatment and prevent ive agents. As a commercial venture, BCN… More

Botanical-derived drug discovery for cancer therapy

Award Year / Program / Phase:
2008 / SBIR / Phase I
Award Amount:
$130,207.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): In a screen for naturally occurring angiogenic inhibitors, we have identified an extract from the plant Livistona chinensis, which has potent anti-angiogenic and anti-tumor activity and is non-toxic in mice. To our know ledge, ours is the first publication in the… More

A novel targeted therapy

Award Year / Program / Phase:
2010 / SBIR / Phase I
Award Amount:
$160,735.00
Agency:
HHS
Principal Investigator:
Brian Varnum
Abstract:
DESCRIPTION (provided by applicant): Cancer is the leading cause of mortality in the United States, despite many advances in the current therapies including surgery, radiation and chemotherapy. Therefore, it is imperative that novel targets for cancer ther apeutic development are identified and… More